Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy

Authors: Oliver J. Stoetzer, Debora M. I. Fersching, Christoph Salat, Oliver Steinkohl, Christian J Gabka, Ulrich Hamann, Michael Braun, Axel-Mario Feller, Volker Heinemann, Barbara Siegele, Dorothea Nagel, Stefan Holdenrieder

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

Neoadjuvant chemotherapy in breast cancer patients aims at preoperative reduction of tumor volume for better resection results and prognosis. As not all patients respond to neoadjuvant therapy, predictive biomarkers are needed for more efficient individual management. In prospectively collected sera of 51 consecutive locally confined breast cancer (LBC) patients receiving preoperative, neoadjuvant chemotherapy, value level kinetics of soluble high mobility group box 1 (HMGB1), soluble receptor for advanced glycation end products (sRAGE) as well as the established breast cancer biomarkers CA 15–3 and carcinoembryonic antigen (CEA) were investigated and correlated with therapy response objectified by pathological staging at surgery. In addition, biomarkers were measured in sera of 30 healthy controls (HC), 13 patients with benign breast diseases, and 28 metastatic breast cancer (MBC) patients. Pretherapeutic levels of soluble HMGB1 were decreased in MBC, while sRAGE was already decreased in LBC. In contrast, CA 15–3 and CEA were strongly elevated in MBC, but not in LBC. Combination of sRAGE and CA 15–3 enabled best discrimination of LBC from HC (AUC 78.2 %; sens 58 % at 95 % spec), while CA15-3 and CEA discriminated best between MBC and all controls (AUC 90.9 %; sens 70 % at 95 % spec). In LBC patients undergoing neoadjuvant chemotherapy, nine patients achieved complete remission (CR), 29 achieved partial remission (PR), while 13 had no change of disease (NC). NC patients tended to have higher HMGB1 and lower sRAGE levels before therapy onset (p = 0.056 and p = 0.054), while CA 15–3 and CEA did not predict therapeutic outcome. Furthermore, kinetics of HMGB1 during therapy correlated with efficacy of the treatment (p = 0.053). Markers of immunogenic cell death are valuable for the diagnosis of MBC and early estimation of response to neoadjuvant therapy in LBC patients.
Appendix
Available only for authorised users
Literature
1.
2.
Ozols RF, Herbst RS, Colson YL, et al. American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 2007;25:146–62.PubMedCrossRef
3.
Bundret NJ. Prognostic and predictive factors in breast cancer. Cancer Trial Rev. 2001;27:137–42.CrossRef
4.
Von Minckwitz G. Neoadjuvant chemotherapy in breast cancer—insights from the German experience. Breast Cancer 2012; published online.
5.
EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 2005;365:1687–717.CrossRef
6.
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMedCrossRef
7.
Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRef
8.
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.PubMedCrossRef
9.
Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother. 2008;57:759–75.PubMedCrossRef
10.
Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11–79.PubMedCrossRef
11.
12.
Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Lab Med Sci. 2009;46:1–24.CrossRef
13.
Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88.PubMedCrossRef
14.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.PubMedCrossRef
15.
Holdenrieder S, Stieber P, von Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.PubMedCrossRef
16.
Holdenrieder S, Stieber P, von Pawel J, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci. 2006;1075:244–75.PubMedCrossRef
17.
Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.PubMedCrossRef
18.
19.
Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205:3007–18.PubMedCrossRef
20.
Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death and Differentiation. 2008;15:3–12.PubMedCrossRef
21.
Park JS. G-RF, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al.: High mobility group box 1 protein interacts with multiple toll-like receptors. Am J Physiol Cell Physiol. 2006;290:917–24.CrossRef
22.
Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009;14:364–75.PubMedCrossRef
23.
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.PubMedCrossRef
24.
Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026–30.PubMedCrossRef
25.
Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009;7:38.PubMedCrossRef
26.
Naumnik W, Nilklińska W, Ossolińska M, Chyczewska E. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 2009;47:703–9.PubMedCrossRef
27.
Tang DL, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms. 2010;1799:131–40.CrossRef
28.
Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologica. 2009;52:2251–63.CrossRef
29.
Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of Translational Medicine. 2010;7:17.CrossRef
30.
Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971–8.PubMedCrossRef
31.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
32.
Lehner J, Wittwer C, Fersching D, Siegele B, Holdenrieder S, Stoetzer OJ. Methodical and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res. 2012;32:2059–62.PubMed
33.
Wittwer C, Lehner J, Fersching D, Siegele B, Stoetzer OJ, Holdenrieder S. Methodical and preanalytical evaluation of a RAGE immunoassay. Anticancer Res. 2012;32:2075–78.PubMed
34.
Holdenrieder S, Nagel D, Stieber P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomarkers. 2010;6:179–90.PubMed
35.
Barak V, Holdenrieder S, Nisman B, Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers. 2010;6:191–6.PubMed
36.
Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:36–44.PubMedCrossRef
37.
Holdenrieder S. v Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21–1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res. 2008;14:7813–21.PubMedCrossRef
38.
Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol. 2005;26:44–9.PubMedCrossRef
39.
Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol. 2006;27:235–42.PubMedCrossRef
40.
Stötzer OJ, Fersching DIM, Salat C, Siegele B, Nagel D, Holdenrieder S. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating circulating nucleosomes, DNAse activity, M30 and survivin. Cancer Lett, submitted
41.
Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, Stolzenberg-Solomon RZ. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 2011;71:3582–9.PubMedCrossRef
42.
Krechler T, Jáchymová M, Mestek O, Zák A, Zima T, Kalousová M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem. 2010;43:882–6.PubMedCrossRef
43.
Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1430–8.PubMedCrossRef
44.
Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma. 2010;57:55–61.PubMedCrossRef
45.
Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007;25:720–5.PubMedCrossRef
46.
Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med. 2009;103:1949–53.PubMedCrossRef
47.
Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40:446–52.PubMedCrossRef
48.
Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, Ma Z, Song Q, Wang C. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J. 2009;50:455–64.PubMedCrossRef
49.
Urbonaviciute V, Fürnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007;81:67–74.PubMedCrossRef
50.
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281–93.PubMedCrossRef
51.
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P. Importance of CEA and CA 15–3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27:1963–8.PubMed
52.
Molina R, Gion M, Gressner A, Troalen F, Auge JM, Holdenrieder S, Zancan M, Wycislo M, Stieber P. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System. Clin Chem Lab Med. 2008;46:612–22.PubMedCrossRef
Metadata
Title
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
Authors
Oliver J. Stoetzer
Debora M. I. Fersching
Christoph Salat
Oliver Steinkohl
Christian J Gabka
Ulrich Hamann
Michael Braun
Axel-Mario Feller
Volker Heinemann
Barbara Siegele
Dorothea Nagel
Stefan Holdenrieder
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0513-1

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue

Research Article

TAGLN suppresses proliferation and invasion, and induces apoptosis of colorectal carcinoma cells

Research Article

EphB4 is overexpressed in gliomas and promotes the growth of glioma cells

Research Article

Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo

Research Article

KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer

Research Article

Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma

Research Article

Expression of the coxsackie and adenovirus receptor in human lung cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits